SCREEN PRINTED CARBON ELECTRODE (SPCE) MODIFIED WITH GNP/ZNO NANOPARTICLES AND MOLECULAR IMPRINTED POLYMER (MIP) FOR SERUM AMYLOID A (SAA) DETECTION
Lung diseases, including asthma, chronic bronchitis, pneumonia, and the impact of COVID-19, are major health issues in Indonesia. Serum Amyloid A (SAA) has been identified as a potential biomarker for monitoring these conditions. However, conventional detection methods often face limitations in sens...
Saved in:
| Main Author: | |
|---|---|
| Format: | Theses |
| Language: | Indonesia |
| Subjects: | |
| Online Access: | https://digilib.itb.ac.id/gdl/view/86841 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Lung diseases, including asthma, chronic bronchitis, pneumonia, and the impact of COVID-19, are major health issues in Indonesia. Serum Amyloid A (SAA) has been identified as a potential biomarker for monitoring these conditions. However, conventional detection methods often face limitations in sensitivity, specificity, and cost. This study aims to develop a biosensor based on screen printed carbon electrode (SPCE) modified with graphene nanoplatelets/zinc oxide nanoparticles (GNP/ZnO-NPs) composite and molecular imprinted polymer (MIP).
The SPCE was modified using the drop-casting method for GNP/ZnO-NPs and electropolymerization for MIP formation. Optimization parameters included pyrrole concentration, electropolymerization cycles, and SAA template removal. Characterization results showed that GNP/ZnO-NPs composite improved the electrode's sensitivity and specificity, while MIP provided high selectivity for SAA. The biosensor exhibited high linearity in the concentration range of 1–50 pg/mL with a detection limit of 0.474 pg/mL. Stability tests demonstrated optimal performance for up to 12 days of storage, while interference tests confirmed the biosensor's resilience against interfering substances such as glucose and ascorbic acid.
This research contributes to the development of cost-effective, sensitive, and selective portable biosensor technology for detecting pulmonary disease biomarkers. This technology holds potential as a diagnostic tool to enhance the efficiency of diagnosis and clinical monitoring of lung diseases. |
|---|